A Randomized, Controlled, Open Label, Multicentre, Parallel-Group, Comparing Safety and Efficacy of Pimecrolimus 1% Topical Cream (Bioconâ??s Formulation) Versus ElidelÂ® 1% Topical Cream (Novartis) in Patients with Atopic Dermatitis. - Race

Biocon Limited0 个研究点目标入组 246 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Male or female patients aged between 2 -75 years
•Patients diagnosed with Atopic Dermatitis as per Hanifin and Rajika diagnostic standards
•Patient is capable of understanding the purposes and risks of the trial and has given written Informed Consent
•Patient has documented evidence that they have been unresponsive to alternative traditional therapies such as topical corticosteroids, or in the investigators opinion, such first line therapy would be deemed inadvisable because of potential risks to the patient.
•Patients with an IGA score of 2 (mild) to 4 (severe) at the time of screening
•Patients with Eczema Area and Severity Index (EASI) score of at least 15 at the time of screening
•Treatment naÃ¯ve patients and/or patients receiving treatments for atopic dermatitis other than pimecrolimus can be included in the study after 3 days of wash out period
•Female patients of child bearing potential, using double barrier method or use a reliable method of contraception during the study

•Patient has clinically infected Atopic Dermatitis at baseline
•Patient with known hypersensitivity to macrolides in general, to pimecrolimus or any excipient of the cream
•Any dermatological condition other than Atopic Dermatitis that in the Investigators opinion may interfere with the evaluation of the patients Atopic Dermatitis
•Patients using non-sedating histamines least 7 days prior to the first dosing day or throughout the study.
•Current diagnosis or history or any disease, which in the Investigators opinion would contraindicate the use of immunosuppressants, including but not limited to human immunodeficiency virus (HIV) and cancer.
•Females who are pregnant, lactating or likely to become pregnant during the study

发起方